Eptifibatide Acetate

Eptifibatide Acetate

Offered By
Product Added On
Jul 16, 2019
View more details
Ms. Yancey Yang
Shenzhen, Guangdong ...More Rm.1-107, Shenzhen Bio-Incubator Base, 10 Gaoxin C.Avc.1st, Nanshan District, Shenzhen, Guangdong, 518057, China

Open Map

Product Details
Product Added OnJul 16, 2019
Product Description

Being a quality-focused manufacturer, exporter and supplier, we are affianced in providing Eptifibatide Acetate to our clients. The provided chemical is extensively demanded for preventing platelet aggregation to treat percutaneous coronary intervention and unstable angina. This chemical is processed by our ingenious professionals using quality-assured chemicals and contemporary techniques in tandem with international standards. Furthermore, we offer this Eptifibatide Acetate to our clients in various packaging options at marginal prices.

Features:Eptifibatide Acetate

  • Longer shelf life

  • Purity

  • High effectiveness

  • Optimum solubility

Active Substance :
Eptifibatide is an inhibitor of platelet aggregation belonging to the class of RGD (arginine-glycine-aspartate) mimetics. Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein (GP) IIb/IIIa receptors. This product is offered and sold solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use or sale of drugs (the Bolar Exemption). JYM cannot be made liable for any infringement of intellectual property rights. It is the sole and only responsibility of the purchaser or user of this product to comply with the relevant national rules and regulations. 

Specification :

  • Molecular Formula C35H49N11O9S2

  • Relative Molecular Mass 831.97 g/mol

  • CAS-Number 188627-80-7 (net), 148031-34-9 (acetate)

  • Long-term Storage-20± 5°C

  • Sequence 3-Mercaptopropionyl-Homoarg-Gly-Asp-Trp-Pro-Cys-NH2 acetate salt  (Disulfide bond)

Fields of Application:

  • Non-urgent percutaneous coronary intervention

  • Unstable angina or non-Q-wave myocardial infarction

Company Details

Shenzhen JYMed Technology Co., Ltd. (JYMed) founded in 2009, is an innovative pharmaceutical enterprise with independent intellectual property rights in R&D, manufacturing and commercialization of peptide products. There are two subsidiary companies of Shenzhen JX Bio Pharmaceutical Co., Ltd. and Hubei JX Bio Pharmaceutical Co., Ltd. It is initiative to establish the R&D technology platform for peptide products and sustained release pharmaceutical preparation of peptide and protein medicines by JYMed in China. The peptide products in R&D are in the forward position in China and aboard, while the technology is in the domestic leading position and international advanced level. Our company has an excellent R&D team, management team and first-class expert consultant team consisting of professionals including doctors, masters, professors, researchers, senior engineers. Meanwhile, to maximally extend the R&D team by hiring top industry scientists to serve as guest researchers, commissioners, and technical consultants and strengthening technical cooperation with external scientific research units. It has established a good cooperative relationship with famous universities and research institutions such as Southwest University, School of Pharmaceutical Science, Sun Yat-Sen University, Hebei University, Research Institute of Tsinghua University, Southern University of Science and Technology, Shenzhen Technology University, and Shenzhen University. The company has passed the certification of Shenzhen High-tech Enterprise and National High-tech Enterprise. As a domestic enterprise with the advantage of the industrialization of polypeptide APIs, it has achieved a major technological breakthrough in the industrialization of polypeptide APIs with extremely high technical difficulty. With high-quality product quality, the company carries out open R&D CRO services. The market network covers domestic and foreign markets. The cooperation customers are mainly domestic and foreign large-scale new drug R&D and production companies. In recent years, JYMedhas been focusing on R&D and production of peptide. At the same time, the company also has been focusing on the development and industrialization. It has been continually increasing investment in high-end chemical drugs and biological drugs, striving for long-term business operations and develop in an all-round way to create a more prominent corporate competitive advantage. The company is adhering to the enterprise spirit of “Tianjianzhishan, Tianyuanzhihe.” We are with a grateful heart and commit to providing reliable medical products for human health all the time. To work hard to become an influential and innovative company in the pharmaceutical industry.

  • BUSINESS TYPE Exporter, Manufacturer, Supplier
  • WORKING DAYS Monday To Sunday
  • PAYMENT MODE Telegraphic Transfer (T/T)
Explore Related Categories
Send Enquiry to Supplier